Novo Nordisk's new weight loss drug, amycretin, shows promising results in phase 1 trials, potentially outperforming Wegovy.
Novo Nordisk's new weight loss drug, amycretin, shows promising results in phase 1 trials, potentially outperforming current drugs like Ozempic and Wegovy. The company's stock has grown 270% over the past three years due to the success of its diabetes and weight loss drugs, including Wegovy, whose sales rose over 400% last year. Novo Nordisk's latest weight loss pill, amycretin, may be more effective than the injectable Wegovy after 12 weeks of trials.
March 21, 2024
6 Articles